>>> US Gapping up

Gapping up
In reaction to earnings/guidance:
  • UMC +9% (Dec revs), AIR +4.1%, PENG +3.9%, KMDA +3% (guidance), PSQH +1.8% (announces leadership updates and preliminary Q4 revenue above guidance)
Other news:
  • VTYX +58.6% (LLY in advanced talks to acquire VTYX according to WSJ)
  • GLUE +28.4% (to present interim MRT-8102 Phase 1 study results)
  • MBLY +10.5% (to acquire Mentee Robotics)
  • EGHT +5.2% (acquires Maven Lab to expand APAC customer engagement capabilities)
  • CMPS +5.2% (FDA acceptance of IND application for PTSD and hosts webinar on PTSD and TRD)
  • ALMS +4.7% (commences $175 mln stock offering)
  • MSTR +4.4% (MSCI announces it will not exclude digital asset treasury cos from MSCI Indexes)
  • CRNX +4% (prices offering of 7.62 mln shares of common stock at $45.95 per share)
  • RZLT +3.7% (announced further insights into the sunRIZE trial; plans to meet with FDA to align on path forward for congenital HI)
  • AZ +3.3% (authorizes $20 million share repurchase program)
  • LGIH +3.1% (reports 4,788 home closings in 2025)
  • GME +2.7% (announces long-term performance award for Ryan Cohen; award incentivizes growth to a market capitalization of $100 billion, aligning compensation directly with stockholder returns)
  • HIVE +2.6% (reports strong December production growth and maintains over 2% of global Bitcoin network)
  • FFAI +2.4% (Announces Stockholders' Day Save the Date for January 7)
  • HCM +1.8% (reports topline results of Phase III Part of ESLIM-02 Trial of Sovleplenib for warm antibody autoimmune hemolytic anemia in China)
  • EVRG +1.7% (partial repurchase of 4.50% Convertible Notes due 2027)
  • TTEK +1.6% (names new CEO)
  • CDNA +1.6% (CareDx and 10x Genomics (TXG) to launch ImmuneScape program -- A multiomics research platform to decode transplant rejection and drug response)
  • MUR +1.5% (achieves appraisal success at Hai Su Vang Field; reaffirms 2026 CAPEX guidance)
  • DRS +1.4% (names new COO)
  • ABX +1.3% (launches asset-based finance strategy)
  • RAPP +1.2% (accelerated initiation of RAP-219 Phase 3 program)